TREATMENT OF REFRACTORY AND RELAPSED ADULT ACUTE-LEUKEMIA USING A UNIFORM CHEMOTHERAPY PROTOCOL

被引：9

作者：

MARTINO, R ^{[1
]}

BRUNET, S ^{[1
]}

SUREDA, A ^{[1
]}

MATEU, R ^{[1
]}

ALTES, A ^{[1
]}

DOMINGOALBOS, A ^{[1
]}

机构：

[1] HOSP SANTA CRUZ & SAN PABLO,DEPT HEMATOL,UNITAT HEMATOL CLIN,E-08025 BARCELONA,SPAIN

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷 / 5-6期

关键词：

ADULT ACUTE LEUKEMIA; RELAPSED; REFRACTORY; CHEMOTHERAPY;

D O I：

10.3109/10428199309067931

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty-nine adult patients with relapsed (21) or refractory (8) de novo acute leukemia (12 ALL and 17 ANLL) were treated with a remission-induction salvage chemotherapeutic protocol including vindesine, mitoxantrone, cyclophosphamide, intermediate-dose cytosine arabinoside, prednisolone and methotrexate. Ten of seventeen (59%) ANLL and 8/12 ALL (67%) achieved complete remission (CR). Seven of eight (86%) cases refractory to first-line remission-induction therapy (3/4 ANLL and 4/4 ALL) entered complete remission. The most frequent non-hematologic side effects were gastrointestinal. All patients experienced severe pancytopenia, with median times to recovery of granulocyte and platelet counts of 28 and 29 days, respectively. Nine of twenty-nine (31%) patients suffered febrile episodes of unknown origin and 13/29 (45%) suffered documented infections. Five patients (17%) died while aplastic, four from infection and one from cardiotoxicity. Four patients who entered CR were submitted to a bone marrow transplantation (BMT), two autologous and two allogeneic BMT. Sixteen of the 18 patients who entered CR relapsed, with a median remission duration of 3.5 +/- 2.9 months. Two patients remain in remission at 5+ and 17+ months. These results suggest that this protocol is an effective remission-induction salvage therapy for adult acute leukemias.

引用

页码：393 / 398

页数：6

共 26 条

[11]

Harousseau J.L., Reiffers J., Hurteloup P., Et al., Treatment of relapsed acute myeloid leukaemia with idarubicin and intermediate dose cytarabine, J. Clin. Oncol., 7, pp. 45-49, (1989)

[12]

Lazzarino M., Morra E., Alessandrino E.P., Et al., Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia, Eur. J. He-matol., 43, pp. 411-416, (1989)

[13]

Hiddemann W., Aul C., Maschmeyer G., Et al., High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison, Sem. Hematol., 28, pp. 35-38, (1991)

[14]

Arlin Z.A., Feldman E., Kempin S., Et al., Amsa-crine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults, Blood, 72, pp. 433-435, (1988)

[15]

Kantarjian H.M., Walters R.S., Keating M.J., Barlogie B., McCredie K.B., Freireich E.J., Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphoblastic leukemia, Cancer, 64, pp. 16-22, (1989)

[16]

Kantarjian H.M., Walters R.L., Keating M.J., Et al., Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia, Cancer, 65, pp. 5-8, (1989)

[17]

Milpied N., Gisselbrecht C., Harousseau J.L., Et al., Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone and etoposide (PAME) chemotherapy, Cancer, 66, pp. 621-631, (1990)

[18]

Hiddemann W., Buchner T., Heil G., Et al., Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM), Leukemia, 4, pp. 637-640, (1990)

[19]

Ciolli S., Leoni F., Caporale R., Salti F., Rossi Ferrini P., Et al., Continuous-infusion cyclophosphamide plus vincristine, cytosine arabinoside and prednisone for refractory acute lymphoblastic leukemia in adults, Haematologica, 76, pp. 293-297, (1991)

[20]

Freund M., Diedrich H., Ganser A., Et al., Treatment of relapsed or refractory adult acute lymphocytic leukemia, Cancer, 69, 709, (1991)

← 1 2 3 →